Sensitive
The platform is designed to detect targets at very low concentrations. HIV-1 p24 is the current model system.
TARGET DETECTION
The platform is designed to detect targets at very low concentrations. HIV-1 p24 is the current model system.
Diagnostics, closer to the point of care
Femtova Dx is developing a portable testing platform for low-concentration biomarker detection, with HIV-1 p24 as its model system.
A point-of-care lateral flow assay platform in development
The opportunity
Many testing pathways rely on centralized laboratory workflows. We are developing tools that bring biomarker detection closer to the point of care.
The platform
A lateral flow assay format paired with a portable reader. Designed around practical detection needs and a path toward additional biomarkers.
The platform is designed to detect targets at very low concentrations. HIV-1 p24 is the current model system.
TARGET DETECTION
The platform is designed to detect targets at very low concentrations. HIV-1 p24 is the current model system.
A compact reader prototype is being developed alongside the lateral flow assay.
READER PROTOTYPE
A compact reader prototype is being developed alongside the lateral flow assay.
The platform has a multiplex biomarker direction, with additional targets to be defined through future research.
PLATFORM DIRECTION
The platform has a multiplex biomarker direction, with additional targets to be defined through future research.
Build with us
We are looking for collaborators who share our goal of advancing point-of-care diagnostics.
Start a conversationCo-development and licensing
Study design and validation
Grant and investment partners
The people
A founding team building at the intersection of diagnostics, engineering, and research.
FOUNDING TEAMBiography to be provided.
FOUNDING TEAMBiography to be provided.
Governance
Director names and biographies will be added after approval.
Contact
Interested in working with us? Send a note to start a conversation.
Contact details to be confirmed